Masimo (MASI)
(Delayed Data from NSDQ)
$106.44 USD
-1.65 (-1.53%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $106.33 -0.11 (-0.10%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$106.44 USD
-1.65 (-1.53%)
Updated Jul 30, 2024 04:00 PM ET
After-Market: $106.33 -0.11 (-0.10%) 7:58 PM ET
2-Buy of 5 2
C Value C Growth D Momentum C VGM
Zacks News
Will Robust ICL Sales Aid STAAR Surgical (STAA) Q3 Earnings?
by Zacks Equity Research
STAAR Surgical (STAA) is expected to pitch in a solid top-line contribution with its Implantable Collamer Lens (ICL) consisting of the EVO Visian ICL product line.
Will Amedisys' (AMED) Q3 Earnings Reflect Overall Gain?
by Zacks Equity Research
Amedisys' (AMED) Q3 is anticipated to benefit from a strong uptick across all its three business lines consisting of Home Health, Hospice and Personal Care.
LabCorp (LH) Q3 Earnings Lag Estimates, Guidance Tweaked
by Zacks Equity Research
Within LabCorp (LH) Diagnostics business the disposition of certain businesses and the implementation of the Protecting Access to Medicare Act (PAMA) dented growth.
Thermo Fisher (TMO) Beats on Q3 Earnings, Ups '18 Guidance
by Zacks Equity Research
Thermo Fisher (TMO) raises its 2018 revenue view, banking on a solid third-quarter operational performance, partially offset by a less favorable foreign exchange.
Edwards Lifesciences (EW) Earnings Beat, Revenues Miss in Q3
by Zacks Equity Research
Edwards Lifesciences (EW) gains from THVT strength on continued therapy adoption across all geographies in Q3.
Masimo (MASI) Q3 Earnings Preview: What to Look Out For
by Zacks Equity Research
Masimo (MASI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Illumina (ILMN) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
Illumina (ILMN) gains on strong consumables growth across its sequencing portfolio with strength in all throughput categories and microarray business in Q3.
Is Masimo (MASI) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (MASI) Outperforming Other Medical Stocks This Year?
Boston Scientific (BSX) Beats on Q3 Earnings, Misses Revenues
by Zacks Equity Research
Boston Scientific (BSX) registers steady growth across all business lines and geographies in Q3.
Can Diagnostic Revenues Drive PerkinElmer (PKI) Q3 Earnings?
by Zacks Equity Research
PerkinElmer (PKI) likely to gain from strong segmental revenues in Q3; a raised earnings guidance for 2018 is promising.
Can Medication Delivery Unit Aid Baxter's (BAX) Q3 Earnings?
by Zacks Equity Research
Baxter (BAX) likely to gain from strong Medication Delivery revenues; guidance for 2018 raised.
Will Healthcare Arm Drive BioTelemetry's (BEAT) Q3 Earnings?
by Zacks Equity Research
Product launches, synergies from LifeWatch acquisition and favorable payor mix are expected to have worked in favor of BioTelemetry's (BEAT) Healthcare arm in Q3.
Quest Diagnostics (DGX) Q3 Earnings Meet, Guidance Tweaked
by Zacks Equity Research
Quest Diagnostics (DGX) gains on successful execution of its strategy of accelerating growth in Q3.
PetMed (PETS) Q2 Earnings Grow Y/Y, Reorder Sales Solid
by Zacks Equity Research
PetMed's (PETS) reorder sales growth solid in Q2. Increased online sales buoy optimism.
What's in Store for Medpace Holdings (MEDP) in Q3 Earnings?
by Zacks Equity Research
Medpace Holdings' (MEDP) revenue growth in Q3 to be driven by strength in oncology, cardiometabolic, antiviral and anti-infectious diseases solutions.
Will Global Industrial Unit Boost Ecolab's (ECL) Q3 Earnings?
by Zacks Equity Research
Solid performance in the Global Industrial segment to drive Ecolab's (ECL) Q3 results.
Will Core MedSurg Segment Aid Stryker's (SYK) Q3 Earnings?
by Zacks Equity Research
Stryker (SYK) is likely to gain from strong segmental performance in Q3; softness anticipated in Spine business.
Will Core Business Units Aid McKesson's (MCK) Q2 Earnings?
by Zacks Equity Research
McKesson (MCK) is expected to gain from strong segmental performances in Q2 of fiscal 2019.
LabCorp (LH) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
LabCorp (LH) might sustain its winning streak in third-quarter 2018 after having retained the same for the past few quarters. However, reimbursement pressure remains a concern.
Can Overall Growth Drive Thermo Fisher (TMO) Q3 Earnings?
by Zacks Equity Research
Thermo Fisher's (TMO) steadily strong analytical instrument business flaunts higher global demand.
Will Boston Scientific's (BSX) Q3 Earnings Reflect Overall Gain?
by Zacks Equity Research
We are optimistic about the IC business that will help Boston Scientific (BSX) maintain impressive global growth, owing to an innovative portfolio and robust commercial teams.
Can Abbott's (ABT) Steady Overall Growth Aid Q3 Earnings?
by Zacks Equity Research
Abbott (ABT) is consistently well-placed on a healthy growth trajectory within its Diabetes Care business for the past few quarters.
Here's Why You Should Invest in GNC Holdings (GNC) Right Now
by Zacks Equity Research
GNC Holdings (GNC) registers strong performance in e-commerce business and International segment. In fact, the company is putting an all-out effort to strengthen its international presence.
What's in Store for Cerner (CERN) This Earnings Season?
by Zacks Equity Research
Cerner's (CERN) third-quarter 2018 results are likely to be hurt by soft segmental results; guidance promising.
Will Instruments Drive Intuitive Surgical (ISRG) Q3 Earnings?
by Zacks Equity Research
Strong prospects in the Instruments and Accessories segment to drive Intuitive Surgical???s (ISRG) top line in the third quarter of 2018.